EU5 Neuromodulation Devices Market Outlook to 2033 – Implantable Neuromodulation Devices and Non-Invasive Neuromodulation Devices

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$5995

GlobalData’s “EU5 Neuromodulation Devices Outlook to 2033” is a comprehensive databook report, covering key market data on the EU5 Neuromodulation Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Implantable Neuromodulation Devices, Minimally Invasive Neuromodulation Devices and Non-Invasive Neuromodulation Devices

The EU5 Neuromodulation Devices Market report provides key information and data on:
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2025 company share data for Neuromodulation Devices Market.
• Global corporate-level profiles of key companies operating within the EU5 Neuromodulation Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

EU5 Neuromodulation Devices is segmented as follows:

• Implantable Neuromodulation Devices

• Minimally Invasive Neuromodulation Devices

• Non-Invasive Neuromodulation Devices

Reasons to Buy

The EU5 Neuromodulation Devices Market report helps you to develop:

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Neuromodulation Devices Market Segmentation

2.3 Definitions of Markets Covered in the Report

3 Neuromodulation Devices Market, EU5

3.1 Neuromodulation Devices Market, EU5, Revenue ($m), 2018-2033

3.2 Neuromodulation Devices Market, EU5, Revenue ($m), 2018-2033

3.3 Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033

3.4 Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033

3.5 Neuromodulation Devices Market, EU5, Company Share by Revenue ($m), 2025

4 Neuromodulation Devices Market, France

4.1 Neuromodulation Devices Market, France, Revenue ($m), 2018-2033

4.1.1 Implantable Neuromodulation Devices Market, France, Revenue ($m), by Segment, 2018-2033

4.2 Neuromodulation Devices Market, France, Volume (Units), 2018-2033

4.2.1 Implantable Neuromodulation Devices Market, France, Volume (Units), by Segment, 2018-2033

4.3 Neuromodulation Devices Market, France, Average Price ($), 2018-2033

4.4 Neuromodulation Devices Market, France, Company Share by Revenue ($m), 2025

5 Neuromodulation Devices Market, Germany

5.1 Neuromodulation Devices Market, Germany, Revenue ($m), 2018-2033

5.1.1 Implantable Neuromodulation Devices Market, Germany, Revenue ($m), by Segment, 2018-2033

5.2 Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033

5.2.1 Implantable Neuromodulation Devices Market, Germany, Volume (Units), by Segment, 2018-2033

5.3 Neuromodulation Devices Market, Germany, Average Price ($), 2018-2033

5.4 Neuromodulation Devices Market, Germany, Company Share by Revenue ($m), 2025

6 Neuromodulation Devices Market, Italy

6.1 Neuromodulation Devices Market, Italy, Revenue ($m), 2018-2033

6.1.1 Implantable Neuromodulation Devices Market, Italy, Revenue ($m), by Segment, 2018-2033

6.2 Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033

6.2.1 Implantable Neuromodulation Devices Market, Italy, Volume (Units), by Segment, 2018-2033

6.3 Neuromodulation Devices Market, Italy, Average Price ($), 2018-2033

6.4 Neuromodulation Devices Market, Italy, Company Share by Revenue ($m), 2025

7 Neuromodulation Devices Market, Spain

7.1 Neuromodulation Devices Market, Spain, Revenue ($m), 2018-2033

7.1.1 Implantable Neuromodulation Devices Market, Spain, Revenue ($m), by Segment, 2018-2033

7.2 Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033

7.2.1 Implantable Neuromodulation Devices Market, Spain, Volume (Units), by Segment, 2018-2033

7.3 Neuromodulation Devices Market, Spain, Average Price ($), 2018-2033

7.4 Neuromodulation Devices Market, Spain, Company Share by Revenue ($m), 2025

8 Neuromodulation Devices Market, United Kingdom

8.1 Neuromodulation Devices Market, United Kingdom, Revenue ($m), 2018-2033

8.1.1 Implantable Neuromodulation Devices Market, United Kingdom, Revenue ($m), by Segment, 2018-2033

8.2 Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033

8.2.1 Implantable Neuromodulation Devices Market, United Kingdom, Volume (Units), by Segment, 2018-2033

8.3 Neuromodulation Devices Market, United Kingdom, Average Price ($), 2018-2033

8.4 Neuromodulation Devices Market, United Kingdom, Company Share by Revenue ($m), 2025

9 Overview of Key Companies in EU5 Neuromodulation Devices Market

9.1 Medtronic Plc

9.1.1 Company Overview

9.2 Boston Scientific Corp

9.2.1 Company Overview

9.3 Abbott Laboratories

9.3.1 Company Overview

9.4 LivaNova Plc

9.4.1 Company Overview

9.5 Nevro Corp

9.5.1 Company Overview

9.6 Enterra Medical Inc

9.6.1 Company Overview

9.7 Axonics Inc

9.7.1 Company Overview

10 Neuromodulation Devices Market Pipeline Products

11 Recent Developments

11.1 Corporate Communications

11.1.1 Nov 11, 2025: Novel Technique Enhances Brain-State Detection

11.1.2 Nov 05, 2025: Waardenburg Syndrome and Piebaldism

11.1.3 Nov 04, 2025: CSIC Receives Two Technological Prototypes from CDTI for Neurological Disease Therapies

11.1.4 Nov 03, 2025: Neurovalens Secures £6m Funding

11.1.5 Oct 29, 2025: Neurosurgery Clinic of SZU and UNB Pioneers Minimally Invasive Treatment of Brain Hemorrhage in Central Europe

11.1.6 Oct 23, 2025: New MRgFUS Machine Supported With 5 Million Kroner

11.1.7 Oct 21, 2025: New Electrode System Provides Insights into Spinal Cord Function

11.1.8 Oct 16, 2025: IXICO CEO Bram Goorden Discusses Strong 2025 Performance And 2026 Priorities

11.1.9 Oct 06, 2025: GSK Appoints Luke Miels As CEO Designate

11.1.10 Sep 19, 2025: SensoDetect Strengthens Global Clinical Leadership: Dr. Mohamed Hussein Atwa Ahmed Now Permanently Based in Sweden to Drive Expansion and Investor Value

11.1.11 Sep 16, 2025: Sant Pau Integrates Hifu in New Brain Neuromodulation Unit

11.1.12 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces

11.1.13 Sep 08, 2025: Changes To The Executive Board Of Carl Zeiss AG

11.1.14 Sep 08, 2025: Immunotherapy Before Surgery Shows Promise for Rare Lung Cancer Treatment

11.1.15 Aug 19, 2025: Medtronic Appoints John Groetelaars and Bill Jellison as Independent Directors

11.1.16 Jul 08, 2025: Medtronic Appoints Chad Spooner as Chief Financial Officer of MiniMed

11.1.17 Jun 24, 2025: GSK Announces Director Declaration

11.1.18 Jun 09, 2025: Nottinghamshire Healthcare receives funding for infrastructure improvements

11.1.19 May 21, 2025: Medtronic Announces Leadership Change in Cardiovascular Portfolio

11.1.20 Mar 25, 2025: CorTec Names Frank Desiere as Chief Executive Officer

11.2 Financial Announcements

11.2.1 Jan 29, 2026: Sanofi Releases 2025 Strong Sales and EPS Growth

11.2.2 Sep 02, 2025: Boston Scientific Announces 2025 Investor Day Meeting and Conference Call Discussing Third Quarter 2025 Results

11.2.3 Jul 31, 2025: Sanofi Q2: Double-Digit Sales and Solid Business EPS Growth

11.2.4 Jul 24, 2025: Avanos Medical to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

11.2.5 May 07, 2025: Medtronic to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2025

11.3 Government and Public Interest

11.3.1 Sep 30, 2025: Sequana Medical Features Alfapump System at 2025 Portal Intervention Symposium

11.3.2 Sep 02, 2025: Compelling Data at ESC Congress 2025 Reinforce Safety and Performance of the Medtronic Omniasecure Defibrillation Lead, Including in the Left Bundle Branch Area

11.3.3 Aug 29, 2025: Medtronic Executives to Speak at Upcoming Investor Conferences

11.3.4 Aug 22, 2025: LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

11.3.5 May 23, 2025: Medtronic Chairman and CEO Geoff Martha to Speak at Bernstein's Strategic Decisions Conference

11.4 Other Significant Developments

11.4.1 Jan 29, 2026: Sanofi Releases 2025 Strong Sales and EPS Growth

11.4.2 Nov 21, 2025: Sant Pau Incorporates Transcranial Magnetic Stimulation Device With Help From Asunción Llauradó de Febrer Foundation

11.4.3 Nov 20, 2025: Nexstim Receives NBS 6 System Order From New Research Customer

11.4.4 Nov 04, 2025: CSIC Receives Two Technological Prototypes from CDTI for Neurological Disease Therapies

11.4.5 Nov 03, 2025: Cefaly Achieves Milestone as Most Prescribed Neuromodulation Device by Veterans Health Administration

11.4.6 Oct 29, 2025: Neurosurgery Clinic of SZU and UNB Pioneers Minimally Invasive Treatment of Brain Hemorrhage in Central Europe

11.4.7 Oct 27, 2025: Nexstim Receives Order for NBS 6 System from Finnish Hospital

11.4.8 Oct 16, 2025: IXICO CEO Bram Goorden Discusses Strong 2025 Performance And 2026 Priorities

11.4.9 Oct 14, 2025: Nexstim Secures Order for NBS 6 Therapy System from Private Medical Center in Finland

11.4.10 Oct 13, 2025: Onward Medical Provides Q3 2025 Update on ARC-EX Adoption

11.4.11 Oct 07, 2025: Nexstim Receives System Order From US Clinic

11.4.12 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington

11.4.13 Jul 31, 2025: Sanofi Q2: Double-Digit Sales and Solid Business EPS Growth

11.5 Product News

11.5.1 Jan 14, 2026: TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics

11.5.2 Nov 21, 2025: Brainbox and Sonic Concepts Deliver 100 NeuroFUS Systems Worldwide

11.5.3 Nov 21, 2025: Sant Pau Incorporates Transcranial Magnetic Stimulation Device With Help From Asunción Llauradó de Febrer Foundation

11.5.4 Nov 17, 2025: BrainsWay Launches Clinical Trial of Deep TMS 360 System for Alcohol Use Disorder

11.5.5 Nov 05, 2025: MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients

11.5.6 Nov 03, 2025: Cefaly Achieves Milestone as Most Prescribed Neuromodulation Device by Veterans Health Administration

11.5.7 Nov 03, 2025: Neurovalens Secures £6m Funding

11.5.8 Oct 31, 2025: European Investment Bank Supports German MedTech with €20 Million for PRECISIS

11.5.9 Oct 31, 2025: New Project Aims to Transform Implantable Medical Devices

11.5.10 Oct 30, 2025: Sant Pau Incorporates MRgFUS Technology For Movement Disorders Without Surgery

11.5.11 Oct 27, 2025: Nexstim Receives Order for NBS 6 System from Finnish Hospital

11.5.12 Oct 21, 2025: New Electrode System Provides Insights into Spinal Cord Function

11.5.13 Oct 20, 2025: Neupulse Attends Launch of N3 Centre for Neurotechnology

11.5.14 Oct 16, 2025: First Brain-Computer Interface Implantation for Paralysis in Europe

11.5.15 Oct 14, 2025: Nexstim Secures Order for NBS 6 Therapy System from Private Medical Center in Finland

11.5.16 Oct 13, 2025: Onward Medical Provides Q3 2025 Update on ARC-EX Adoption

11.5.17 Sep 30, 2025: Sequana Medical Features Alfapump System at 2025 Portal Intervention Symposium

11.5.18 Sep 19, 2025: Medtronic Receives FDA Approval for Altaviva Device to Treat Urge Urinary Incontinence

11.5.19 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington

11.5.20 Sep 16, 2025: Sant Pau Integrates Hifu in New Brain Neuromodulation Unit

11.5.21 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces

11.5.22 Sep 10, 2025: Neurocare Group's Apollo TMS Therapy Devices Granted FDA Clearance for Treating Adolescent Depression

11.5.23 Sep 08, 2025: Onward Medical Receives CE Mark for Arc-Ex, Enabling Commercial Launch in Europe

11.5.24 May 28, 2025: Nyxoah to Present at the Jefferies Global Healthcare Conference

11.5.25 May 27, 2025: CEFALY Technology Announces Launch of CEFALY@Work

11.6 Strategy And Business Planning

11.6.1 Nov 24, 2025: Johnson & Johnson Expands Neurovascular Research and Development Activities in Galway

11.6.2 Nov 21, 2025: Brainbox and Sonic Concepts Deliver 100 NeuroFUS Systems Worldwide

11.6.3 Nov 13, 2025: Partnership Enhances Patient Access to Neurotechnologies

11.6.4 Nov 10, 2025: Inbrain Neuroelectronics Collaborates With Microsoft to Enhance Agentic AI for Neurology and Brain-Computer Interfaces

11.6.5 Nov 06, 2025: Medical University of Innsbruck Joins NeurotechEU Alliance

11.6.6 Nov 04, 2025: Zeiss Opens New Quality Excellence Center in Connecticut

11.6.7 Nov 03, 2025: Neurovalens Secures £6m Funding

11.6.8 Oct 31, 2025: European Investment Bank Supports German MedTech with €20 Million for PRECISIS

11.6.9 Oct 20, 2025: Neupulse Attends Launch of N3 Centre for Neurotechnology

11.6.10 Oct 16, 2025: IXICO CEO Bram Goorden Discusses Strong 2025 Performance And 2026 Priorities

11.6.11 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington

11.6.12 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces

12 Appendix

12.1 Research Methodology

12.1.1 Coverage

12.1.2 Secondary Research

12.1.3 Primary Research

12.1.4 Market Modeling and Forecasting

12.1.5 Company Share Analysis

12.1.6 Benchmarking

12.2 GlobalData Consulting

12.3 Contact Us

12.4 Disclaimer

Table

Table 1: Neuromodulation Devices Market, Cross Country Comparison, EU5, Revenue ($m), USD Constant, 2018-2033

Table 2: Neuromodulation Devices Market, EU5, Revenue ($m), USD Constant, 2018-2033

Table 3: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033

Table 4: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033

Table 5: Neuromodulation Devices Market, EU5, Company Share by Revenue ($m), 2025

Table 6: Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033

Table 7: Implantable Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033

Table 8: Neuromodulation Devices Market, France, Volume (Units), 2018-2033

Table 9: Implantable Neuromodulation Devices Market, France, Volume (Units), 2018-2033

Table 10: Neuromodulation Devices Market, France, Average Price ($), 2018-2033

Table 11: Neuromodulation Devices Market, France, Company Share by Revenue ($m), 2025

Table 12: Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033

Table 13: Implantable Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033

Table 14: Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033

Table 15: Implantable Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033

Table 16: Neuromodulation Devices Market, Germany, Average Price ($), 2018-2033

Table 17: Neuromodulation Devices Market, Germany, Company Share by Revenue ($m), 2025

Table 18: Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033

Table 19: Implantable Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033

Table 20: Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033

Table 21: Implantable Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033

Table 22: Neuromodulation Devices Market, Italy, Average Price ($), 2018-2033

Table 23: Neuromodulation Devices Market, Italy, Company Share by Revenue ($m), 2025

Table 24: Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033

Table 25: Implantable Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033

Table 26: Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033

Table 27: Implantable Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033

Table 28: Neuromodulation Devices Market, Spain, Average Price ($), 2018-2033

Table 29: Neuromodulation Devices Market, Spain, Company Share by Revenue ($m), 2025

Table 30: Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033

Table 31: Implantable Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033

Table 32: Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033

Table 33: Implantable Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033

Table 34: Neuromodulation Devices Market, United Kingdom, Average Price ($), 2018-2033

Table 35: Neuromodulation Devices Market, United Kingdom, Company Share by Revenue ($m), 2025

Table 36: Neuromodulation Devices Market Pipeline Products

Table 37: Total Number of Primary Research Participants, Neurology Devices Market, by Country

Figures

Figure 1: Neuromodulation Devices Market, Cross Country Comparison, EU5, Revenue ($m), USD Constant, 2018-2033

Figure 2: Neuromodulation Devices Market, EU5, Revenue ($m), USD Constant, 2018-2033

Figure 3: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033

Figure 4: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033

Figure 5: Neuromodulation Devices Market, EU5, Company Share (%), 2025

Figure 6: Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033

Figure 7: Implantable Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033

Figure 8: Neuromodulation Devices Market, France, Volume (Units), 2018-2033

Figure 9: Implantable Neuromodulation Devices Market, France, Volume (Units), 2018-2033

Figure 10: Neuromodulation Devices Market, France, Company Share (%), 2025

Figure 11: Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033

Figure 12: Implantable Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033

Figure 13: Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033

Figure 14: Implantable Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033

Figure 15: Neuromodulation Devices Market, Germany, Company Share (%), 2025

Figure 16: Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033

Figure 17: Implantable Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033

Figure 18: Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033

Figure 19: Implantable Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033

Figure 20: Neuromodulation Devices Market, Italy, Company Share (%), 2025

Figure 21: Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033

Figure 22: Implantable Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033

Figure 23: Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033

Figure 24: Implantable Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033

Figure 25: Neuromodulation Devices Market, Spain, Company Share (%), 2025

Figure 26: Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033

Figure 27: Implantable Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033

Figure 28: Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033

Figure 29: Implantable Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033

Figure 30: Neuromodulation Devices Market, United Kingdom, Company Share (%), 2025

EU5 Neuromodulation Devices Market Outlook to 2033 – Implantable Neuromodulation Devices and Non-Invasive Neuromodulation Devices standard reports
Currency USD
$5,995

Can be used by individual purchaser only

$17,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EU5 Neuromodulation Devices Market Outlook to 2033 – Implantable Neuromodulation Devices and Non-Invasive Neuromodulation Devices in real time.

  • Access a live EU5 Neuromodulation Devices Market Outlook to 2033 – Implantable Neuromodulation Devices and Non-Invasive Neuromodulation Devices dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.